| Characteristic | U.S. Medicaid | U.S. Department of Veterans Affairs | Canada | Australia | United Kingdom |
|---|---|---|---|---|---|
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Download
Source
Sources
Release date
April 2015
More information
Region
Worldwide, United States
Survey time period
2013 and 2014
Supplementary notes
MS: multiple sclerosis
Further sources: Pharmaceutical Benefits Scheme (Australia), Ontario Ministry of Health and Long-Term Care (Canada), British National Formulary (UK).
* Interfereon-ß-1b is marketed as Betaseron (Bayer) and Extavia (Novartis).
** Natalizumab was withdrawn from the market in February 2005 to evaluate progressive multifocal leukoencephalopathy risk and was reintroduced in June 2006.
*** Price pending in Canada.
Citation formats
